BR112017026292A2 - muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico - Google Patents
muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnósticoInfo
- Publication number
- BR112017026292A2 BR112017026292A2 BR112017026292A BR112017026292A BR112017026292A2 BR 112017026292 A2 BR112017026292 A2 BR 112017026292A2 BR 112017026292 A BR112017026292 A BR 112017026292A BR 112017026292 A BR112017026292 A BR 112017026292A BR 112017026292 A2 BR112017026292 A2 BR 112017026292A2
- Authority
- BR
- Brazil
- Prior art keywords
- lag
- binding
- patients
- mutein
- lipocalin muteins
- Prior art date
Links
- 102000019298 Lipocalin Human genes 0.000 title abstract 9
- 108050006654 Lipocalin Proteins 0.000 title abstract 9
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 238000009007 Diagnostic Kit Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 230000008105 immune reaction Effects 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176740 | 2015-07-15 | ||
| PCT/EP2016/066909 WO2017009456A1 (en) | 2015-07-15 | 2016-07-15 | Novel proteins specific for lag-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017026292A2 true BR112017026292A2 (pt) | 2018-09-11 |
Family
ID=53719645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017026292A BR112017026292A2 (pt) | 2015-07-15 | 2016-07-15 | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501510B2 (enExample) |
| EP (1) | EP3322433B1 (enExample) |
| JP (1) | JP7108535B2 (enExample) |
| KR (1) | KR20180029238A (enExample) |
| CN (1) | CN108348573A (enExample) |
| AU (1) | AU2016293101B2 (enExample) |
| BR (1) | BR112017026292A2 (enExample) |
| CA (1) | CA2988831A1 (enExample) |
| EA (1) | EA201890198A1 (enExample) |
| MX (1) | MX2018000447A (enExample) |
| WO (1) | WO2017009456A1 (enExample) |
| ZA (1) | ZA201708041B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2988831A1 (en) | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| BR112018076519A8 (pt) | 2016-06-20 | 2022-07-12 | F Star Delta Ltd | Moléculas de ligação que se ligam a pd-l1 e lag-3 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| SG11201906509WA (en) * | 2017-01-18 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| AU2019301204B2 (en) | 2018-07-12 | 2025-10-23 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| WO2020201038A1 (en) | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| JP2023527908A (ja) | 2020-06-05 | 2023-06-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | ４－１ｂｂをターゲティングする多量体免疫調節物質 |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CN1170543C (zh) | 1998-06-08 | 2004-10-13 | 弗·哈夫曼-拉罗切有限公司 | PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19983957B4 (de) | 1999-06-02 | 2008-08-21 | Alstom | Beschichtungszusammensetzung für Hochtemperturschutz |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| EP1596871A4 (en) | 2003-02-28 | 2006-08-23 | Drew M Pardoll | T-CELL REGULATION |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| CN101932598B (zh) * | 2008-01-30 | 2016-12-21 | 皮里斯股份公司 | 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法 |
| US9572863B2 (en) | 2011-12-13 | 2017-02-21 | Pieris Pharmaceuticals Gmbh | Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| EP3441400B1 (en) * | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RS64002B1 (sr) | 2015-05-18 | 2023-03-31 | Pieris Pharmaceuticals Gmbh | Anti-kancerski fuzioni polipeptid |
| CA2988831A1 (en) | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| SG11201906509WA (en) | 2017-01-18 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
-
2016
- 2016-07-15 CA CA2988831A patent/CA2988831A1/en active Pending
- 2016-07-15 CN CN201680040702.XA patent/CN108348573A/zh active Pending
- 2016-07-15 EA EA201890198A patent/EA201890198A1/ru unknown
- 2016-07-15 AU AU2016293101A patent/AU2016293101B2/en not_active Ceased
- 2016-07-15 US US15/744,531 patent/US10501510B2/en active Active
- 2016-07-15 WO PCT/EP2016/066909 patent/WO2017009456A1/en not_active Ceased
- 2016-07-15 MX MX2018000447A patent/MX2018000447A/es unknown
- 2016-07-15 EP EP16742220.3A patent/EP3322433B1/en active Active
- 2016-07-15 KR KR1020187004176A patent/KR20180029238A/ko not_active Ceased
- 2016-07-15 BR BR112017026292A patent/BR112017026292A2/pt not_active IP Right Cessation
- 2016-07-15 JP JP2018501349A patent/JP7108535B2/ja active Active
-
2017
- 2017-11-27 ZA ZA2017/08041A patent/ZA201708041B/en unknown
-
2019
- 2019-10-30 US US16/669,281 patent/US10927156B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180029238A (ko) | 2018-03-20 |
| WO2017009456A1 (en) | 2017-01-19 |
| AU2016293101B2 (en) | 2022-06-16 |
| US10927156B2 (en) | 2021-02-23 |
| EP3322433B1 (en) | 2023-05-31 |
| US20200048317A1 (en) | 2020-02-13 |
| CN108348573A (zh) | 2018-07-31 |
| US20190031729A1 (en) | 2019-01-31 |
| MX2018000447A (es) | 2018-08-15 |
| AU2016293101A1 (en) | 2018-02-22 |
| EA201890198A1 (ru) | 2018-07-31 |
| EP3322433A1 (en) | 2018-05-23 |
| ZA201708041B (en) | 2020-07-29 |
| CA2988831A1 (en) | 2017-01-19 |
| US10501510B2 (en) | 2019-12-10 |
| JP7108535B2 (ja) | 2022-07-28 |
| JP2018532372A (ja) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017026292A2 (pt) | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| AR129651A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
| BR112017020434A2 (pt) | polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| BR112017017530A2 (pt) | proteínas específicas para pioverdina e pioquelina | |
| BR112017015773A2 (pt) | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
| BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
| BR112014019459A8 (pt) | Proteínas de ligação à cdim e usos das mesmas | |
| MX2019008434A (es) | Muteínas de lipocalina con afinidad de unión por lag-3. | |
| BR112018006817A2 (pt) | método de tratamento do câncer | |
| BR112015025025A2 (pt) | composições terapêuticas e usos das mesmas | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112019011812A2 (pt) | composições nutricionais contendo butirato e usos das mesmas | |
| BR112016029024A2 (pt) | conjugados e composições de texafirina-pt(iv) para uso na superação da resistência à platina | |
| BR112018006572A2 (pt) | terapia de combinação racional para o tratamento de câncer | |
| BR112013028285A2 (pt) | indução de il-12 usando imunoterapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2731 DE 09-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |